James Wolf, MD
Urology · Austin, TXNPI 1023100492
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $28,584 of the $30,796 with a category attached, or 92.8%. 11 manufacturers reported payments, led by Boston Scientific at 40.1% of the total. Reporting peaked in 2022 at $15,761 and has fallen 96.3% since, to $576 in 2025. Among urology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 41 payments — averaging $751.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$12K
- Ambu Inc.$12K
- Calyxo, Inc.$6K
- Biotissue Holdings Inc.$217
- Stryker$152
- Conmed Corporation$147
- plus $206 from 5 others
Across 16 payments — averaging $5606.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Calyxo, Inc.$90K
What the payments were for
- Consulting fees$28,58493%
- Food & beverage$2,2107%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 7 | $12,362 |
| Ambu Inc. | 3 | $11,559 |
| Calyxo, Inc. | 19 | $6,152 |
| Biotissue Holdings Inc. | 4 | $217 |
| Stryker | 1 | $152 |
| Conmed Corporation | 1 | $147 |
| Progenics Pharmaceuticals, Inc. | 1 | $65 |
| Medtronic | 2 | $60 |
| Heron Therapeutics, Inc. | 1 | $45 |
| Urogen Pharma, Inc. | 1 | $35 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,796 in reported general payments places this provider in the 90th percentile of 878 urology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Potassium Citrate ErPotassium Citrate | 37 | $3,004 |
| Tamsulosin Hcl | 150 | $2,115 |
| Testosterone | 12 | $872 |
| Methenamine Hippurate | 11 | $643 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 11 | $124 |
| Allopurinol | 14 | $21 |
| Oxycodone Hcl | 17 | $19 |
Paid to pharmacies, not to this prescriber.
Other urology in Austin
- Michael TrotterAustin$590K
- Varun SundaramAustin$400K
- Elizabeth MobleyAustin$254K
- Parviz KavoussiAustin$251K
- Peter RuffAustin$168K
- Bryan KansasAustin$120K
- Aaron LavianaAustin$78K
- Kyle KeyesAustin$58K
- Andrew von EschenbachMontgomery$3.2M
- Brian MazzarellaLakeway$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.